Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome
- PMID: 15221428
- DOI: 10.1007/s00467-004-1516-y
Two different therapeutic regimes in patients with sequelae of hemolytic-uremic syndrome
Abstract
Renal disease is the most important long-term complication of hemolytic-uremic syndrome (HUS). A comparative study of renal function was carried out in two groups of patients. Group 1 included 19 children followed for a median of 11 years, 1960-1980, with a low-sodium diet, antihypertensive drugs, and a restricted protein intake in the end stage of renal disease. Group 2 included 26 children treated for a median of 9 years, 1988-2002, on a low-sodium diet, early restriction of protein intake according to recommendations, and angiotensin converting enzyme inhibitors (ACEi). Long-term renal function was assessed by the inverse of the plasma creatinine concentration (1/[Cr]) over time. Linear regression lines were fitted to individual values of 1/[Cr] for each child. Regression coefficients of children in group 1 were all negative, ranging from -0.031 to -0.00043; 7 were significantly different from zero, indicating a linear fall in renal function over time. In contrast, children from group 2 had 11 negative slopes (only 1 significant) and 15 positive slopes, ranging from 0.17893 to -0.3899. Fisher's exact test showed that group 1 had significantly more children with negative slopes than group 2. This comparatively better long-term outcome of renal function in children under contemporary treatment was probably associated with early restriction of protein and use of ACEi.
Similar articles
-
Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.Pediatr Nephrol. 2011 Aug;26(8):1247-54. doi: 10.1007/s00467-011-1867-0. Epub 2011 Apr 30. Pediatr Nephrol. 2011. PMID: 21533629 Clinical Trial.
-
[Treatment of hemolytic uremic syndrome after acute stage].Zhonghua Er Ke Za Zhi. 2006 Mar;44(3):206-9. Zhonghua Er Ke Za Zhi. 2006. PMID: 16624060 Clinical Trial. Chinese.
-
[Hemolytic uremic syndrome. Treatment of secondary glomerulopathy].Medicina (B Aires). 2005;65(6):528-32. Medicina (B Aires). 2005. PMID: 16433483 Spanish.
-
[Ways to inhibit development of chronic renal failure].Ter Arkh. 2000;72(6):9-14. Ter Arkh. 2000. PMID: 10900641 Review. Russian. No abstract available.
-
[Hemolytic and uremic syndrome in the adult].Nephrologie. 2002;23(4):165-71. Nephrologie. 2002. PMID: 12125322 Review. French.
Cited by
-
Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective.Front Pharmacol. 2022 Nov 1;13:968104. doi: 10.3389/fphar.2022.968104. eCollection 2022. Front Pharmacol. 2022. PMID: 36386190 Free PMC article. Review.
-
Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.Pediatr Nephrol. 2013 May;28(5):745-50. doi: 10.1007/s00467-012-2374-7. Epub 2012 Dec 20. Pediatr Nephrol. 2013. PMID: 23250713
-
Levels of urinary transforming growth factor beta-1 in children with D+ hemolytic uremic syndrome.Pediatr Nephrol. 2010 Jun;25(6):1177-80. doi: 10.1007/s00467-009-1434-0. Epub 2010 Feb 16. Pediatr Nephrol. 2010. PMID: 20157739
-
Dynamic evolution of kidney function in patients with STEC-hemolytic uremic syndrome followed for more than 15 years: unexpected changes.Pediatr Nephrol. 2025 Jan;40(1):143-150. doi: 10.1007/s00467-024-06366-w. Epub 2024 Apr 11. Pediatr Nephrol. 2025. PMID: 38602519
-
Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.Pediatr Nephrol. 2011 Aug;26(8):1247-54. doi: 10.1007/s00467-011-1867-0. Epub 2011 Apr 30. Pediatr Nephrol. 2011. PMID: 21533629 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical